At 26 weeks, 37-58% of patients on dulaglutide 1.5 mg achieved the of <7.0%, no weight gain, and no hypoglycaemia.
Dulaglutide 1.5 mg led to significantly higher odds of reaching the composite endpoint compared to metformin, sitagliptin, exenatide twice daily, and insulin glargine.
Patients on dulaglutide 0.75 mg also demonstrated significantly higher odds of achieving the composite endpoint compared to sitagliptin and insulin glargine.
No significant difference in the composite endpoint achievement was observed between dulaglutide 1.5 mg and liraglutide 1.8 mg.
Simplified
AIM: To compare the effectiveness of dulaglutide 1.5 and 0.75 mg with active comparators and placebo with regard to a of glycated haemoglobin (), weight and hypoglycaemia, using post hoc analyses.
METHODS: A logistic regression analysis was performed on the intention-to-treat population, using data from the last observation carried forward, and the composite endpoint of HbA1c <7.0% (53 mmol/mol), no weight gain (≤0 kg) and no hypoglycaemia (glucose <3.0 mmol/l or severe hypoglycaemia) after 26 weeks for each trial in the AWARD programme separately.
RESULTS: At 26 weeks, within each study, 37-58% of patients on dulaglutide 1.5 mg, 27-49% of patients on dulaglutide 0.75 mg, and 9-61% of patients on active comparators achieved the composite endpoint. Significantly more patients reached the composite endpoint with dulaglutide 1.5 mg than with metformin, sitagliptin, exenatide twice daily or insulin glargine: odds ratio (OR) 1.5 [95% confidence interval (CI) 1.0, 2.2; p < 0.05], OR 4.5 (95% CI 3.0, 6.6; p < 0.001), OR 2.6 (95% CI 1.8, 3.7; p < 0.001) and OR 7.4 (95% CI 4.4, 12.6; p < 0.001), respectively, with no difference between dulaglutide 1.5 mg and liraglutide 1.8 mg. In addition, significantly more patients reached the composite endpoint with dulaglutide 0.75 mg than with sitagliptin or insulin glargine: OR 3.3 (95% CI 2.2, 4.8; p < 0.001) and OR 4.5 (95% CI 2.7, 7.8; p < 0.001), respectively.
CONCLUSIONS: Dulaglutide is an effective treatment option, resulting in a similar or greater proportion of patients reaching the HbA1c target of <7.0% (53 mmol/mol), without weight gain or hypoglycaemia compared with active comparators.
Key numbers
1.5
Higher Odds of Achieving Endpoint with Dulaglutide 1.5 mg
Odds ratio for dulaglutide 1.5 mg vs. metformin
37–58%
Achievement Rate
Percentage of patients reaching <7.0%, no weight gain, no hypoglycaemia
27–49%
Achievement Rate for Dulaglutide 0.75 mg
Percentage of patients achieving the endpoint with dulaglutide 0.75 mg
Full Text
We can’t show the full text here under this license.
